Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Ruilin WuDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Negar KhosravianiDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-2348-5173
Ann MansurDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Emilie BoudreauToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.ORCID 0009-0009-6089-6455
Gabrielle E LargozaDepartment of Cell Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID 0009-0004-1268-4320
Suejean ParkDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Dakota GustafsonDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-8374-6331
Sneha RajuInstitute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-9149-5907
Crizza ChingToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Amira KlipCell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Thomas WälchliDivision of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8961-6551
Kathryn L HoweDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-6519-2280
Ivan RadovanovicDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Joshua D WytheDepartment of Cell Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID 0000-0002-3225-2937
Jason E FishDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. jason.fish@utoronto.ca.ORCID 0000-0003-0640-7277
Funding
Decoding the Molecular and Cellular Mechanisms of Mutant KRAS-driven Brain Arteriovenous MalformationsR01HL159159 · NHLBI · UNIVERSITY OF VIRGINIA · PI WYTHE, JOSHUA D. · 2022 to 2025
$2.6M
Canadian Institutes of Health Research (CIHR) PJT155922Canadian Institutes of Health Research (CIHR) PJT173489HHS | National Institutes of Health (NIH) 1R01HL159159NHLBI NIH HHS R01 HL159159
6 · The paper itself
Abstract
Somatic activating KRAS mutations in endothelial cells are the predominant cause of sporadic brain arteriovenous malformations (bAVMs) and also occur in sporadic extracranial AVMs. We found that KRAS
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
KRAS-dependent glycolytic reprogramming of endothelial cells in sporadic arteriovenous malformations. · full record | OpenQuestion